A first look [BE/BA News]

posted by BRB  – Canada, 2022-12-02 19:20 (110 d 08:01 ago) – Posting: # 23379
Views: 2,972

Hi J,
No, it's still there. See lines 260-261:

The number of evaluable subjects in a PK BE study should not be less than 12. For highly variable drug products, a minimum of 24 subjects are recommended for BE assessment.

❝ Almost a complete overhaul. Very detailed. I notice something, they removed the min sample size requirement of n=12 (Unless it's written in later part of the doc)

Complete thread:

UA Flag
 Admin contact
22,548 posts in 4,723 threads, 1,606 registered users;
18 visitors (0 registered, 18 guests [including 11 identified bots]).
Forum time: 03:21 CET (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz